^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HMN-176

    i
    Other names: HMN-176
    Associations

    News

    Trials
    Company:
    Nippon Shinyaku
    Drug class:
    PLK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth. (PubMed, Pharmaceuticals (Basel))
    HMN-214 is a prodrug of HMN-176 and is known to selectively interfere with PLK1 function. In the NB 3D spheroid tumor model, HMN-214 significantly and in a dose-dependent manner inhibits spheroid tumor mass and growth. Overall, our study highlights that targeting PLK1 using HMN-214 is a novel therapeutic approach for NB.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CHEK2 (Checkpoint kinase 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    MYCN amplification
    |
    HMN-176 • HMN-214